The U.K. adopts industry friendly policies and pledges higher medicine spending, while Germany proposes spending cuts and higher industry fees, according to STAT+ analysis.
While Washington fights over most-favored-nation drug pricing, two of Europe's biggest pharmaceutical markets are running opposite experiments at the same time. According to STAT+ analysis by Europe correspondent Andrew Joseph, the U.K. is tilting toward industry-friendly policy and pledging higher medicine spending. Germany, another of the continent's largest drug markets, is moving the other way with proposed spending cuts and higher industry fees.
The split turns the European drug-pricing debate from an abstract argument into a live experiment. Two governments, both dealing with aging populations and tight health budgets, have landed on opposite answers to the same question: does the path to better patient access and a stronger industry run through friendlier prices, or harder ones?
The U.K. shift follows a pressure campaign from both drugmakers and the Trump administration, STAT+ reports. The government has adopted more industry-friendly policies and pledged to spend more on medicines. The specific mechanisms in play are not detailed in the available reporting, which leaves the policy details somewhat opaque.
Germany is heading in the opposite direction. The country is weighing measures that would tighten drug prices and increase what companies pay into the system, according to STAT+. The available reporting does not specify which instruments Berlin is using, but the trajectory is consistent with the country's long-running effort to contain drug spending growth.
What makes the divergence consequential is the audience. The U.S. is "looking on," as STAT+ framed it, because most-favored-nation drug pricing has become central to the Trump administration's effort to lower American drug costs. MFN-style rules effectively peg U.S. prices to the lowest price a drug sells for in a basket of reference countries, on the theory that the U.S. should not keep paying more than its peers.
The U.K.-Germany split is also a stress test of the U.S. approach itself. The Trump administration has used MFN-style benchmarking as a lever to push European governments toward higher prices for American drugmakers, on the theory that other rich countries have been free-riding on U.S. R&D. A Europe that splits between a friendlier U.K. and a tighter Germany means Washington is no longer negotiating with a single bloc on drug pricing. It is watching two governments pursue visibly different strategies at the same time.
If the U.K. approach wins the argument, that friendlier prices bring more launches, more investment, and faster patient access, it gives Washington a market-based case that MFN-style floor pricing is the wrong tool. If Germany's approach wins, that harder pricing delivers budget relief and access without scaring off innovation, it strengthens the U.S. case.
Both paths carry risks that go beyond the industry-versus-budget framing. Industry-friendly policy can mean slower adoption of cost-effective medicines, higher out-of-pocket costs in some therapeutic areas, and rebate structures that concentrate leverage in a handful of large manufacturers. Austerity-leaning policy can mean delayed launches, restricted formularies, and a push from companies to prioritize markets where they can price freely.
The two-track reality also complicates the transatlantic leverage the U.S. has been trying to exercise. MFN-style pressure assumes that lower prices abroad will eventually pull U.S. prices down. It only works if the markets being benchmarked don't respond by raising their own prices to avoid being the cheap reference. A U.K. that tilts industry-friendly and a Germany that tightens could both narrow the gap with U.S. net prices, just in different ways.
What to watch next: whether the U.K. follows through on its higher-spending pledge in the next budget cycle, whether Germany's cabinet formalizes the proposed fee increases, and whether either government publishes comparative access or launch data that would let outside analysts judge which model is actually delivering for patients. The U.S. side matters too. Any executive-branch action on MFN benchmarking will read differently if the European reference prices are themselves moving.